

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.

REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY

ISSN: 1507-1367

e-ISSN: 2083-4640

Brain diffusion MRI biomarkers after oncology treatments

Authors: Mahdi Mohammadi, Shabnam Banisharif, Fatemeh Moradi, Maryam Zamanian, Ghazal Tanzifi, Sadegh Ghaderi

DOI: 10.5603/rpor.98728

Article type: Review paper

Published online: 2024-01-03

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.

Brain diffusion MRI biomarkers after oncology treatments

Running Title: MRI biomarkers after chemoradiotherapys

[10.5603/rpor.98728](#)

Mahdi Mohammadi¹, Shabnam Banisharif², Fatemeh Moradi³, Maryam Zamanian², Ghazal Tanzifi⁴, Sadegh Ghaderi⁵

¹*Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran*

²*Department of Medical Physics, School of Medicine, Isfahan University of Medical Science, Isfahan, Iran*

³*Department of Energy Engineering & Physics, Amirkabir University of Technology (Tehran Polytechnic), Tehran, Iran*

⁴*Department of Nuclear Engineering, Islamic Azad University, Central Tehran Branch, Tehran, Iran*

⁵*Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran*

Address for correspondence: Sadegh Ghaderi, Tehran University of Medical Sciences, Department of Neuroscience and Addiction Studies, Tehran, Iran; e-mail: S_ghaderi@razi.tums.ac.ir

Abstract

In addition to providing a measurement of the tumor's size and dimensions, magnetic resonance imaging (MRI) provides excellent noninvasive radiographic detection of tumor location. The MRI technique is an important modality that has been shown to be useful in the prognosis, diagnosis, treatment planning, and evaluation of response and recurrence in solid cancers. Diffusion-weighted imaging (DWI) is an imaging technique that quantifies water mobility. This imaging approach is good for identifying sub-voxel microstructure of tissues, correlates with tumor cellularity, and has been proven to be valuable in the early assessment of cytotoxic treatment for a variety of malignancies. Diffusion tensor imaging (DTI) is an MRI method that assesses the preferred amount of water transport inside tissues. This enables precise measurements of water diffusion, which changes according to the direction of white matter fibers, their density, and myelination. This measurement corresponds to some related variables: fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), axial diffusivity (AD), and others. DTI biomarkers can detect subtle changes in white matter microstructure and integrity following radiation therapy (RT) or chemoradiotherapy, which may have implications for cognitive function and quality of life. In our study, these indices were evaluated after brain chemoradiotherapy.

Key words: diffusion MRI; brain; chemoradiotherapy; imaging biomarkers; neuroimaging

Introduction

Diffusion-weighted imaging (DWI) quantifies an estimate of water mobility obtained by magnetic resonance imaging (MRI), is useful for assessing sub-voxel microstructure in tissues, correlates with tumor cellularity, and has been shown to be useful in the early evaluation of cytotoxic therapy in a variety of cancers [1–5].

Diffusion tensor imaging (DTI) is a non-invasive MRI-based approach that detects white matter structure more accurately than conventional MRI. Water diffusion in tissues is measured using DTI, an MRI method that analyzes the preferred direction and amount of the water's movement. Water diffusion in white matter tracts is often directionally dependent or anisotropic because of the ordered structure of axons and myelin sheaths. Radiation-induced white matter damage may be evaluated noninvasively using DTI, which has a long history of supporting evidence as an imaging biomarker [6–10].

DTI assesses water molecule diffusion in the brain, which changes with white matter fiber direction, density, and myelination. Mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD) are three related values of this measurement. These indices are related to the magnitudes of diffusion that are perpendicular and parallel to white matter fibers, respectively. The fractional anisotropy (FA) index is another kind of diffusion index that is often employed. It is a normalized value that may vary from zero (which indicates equal diffusion in all directions) to one (diffusion along a single axis only). FA is a measure of the overall density and integrity of the brain's white matter; a reduction in FA has been linked to a wide variety of brain disorders [7, 11–17].

Radiation therapy (RT) for primary brain tumors and brain metastases from extracranial tumors is performed annually on hundreds of thousands of patients around the world [18–23]. There are two types of brain radiotherapy: whole brain (WBRT) and partial brain (PBRT). WBRT involves irradiating the whole brain and brainstem, whereas PBRT involves irradiating the tumor or tumor bed and surrounding margin and some healthy brain tissue [21, 24, 25]. Stereotactic radiosurgery (SRS) uses accurate 3D imaging and localization to deliver ablative doses of radiation to the tumor while exposing healthy brain tissue to a minimum [23, 25].

RT may cause post-treatment neurocognitive deterioration, with verbal and visuospatial memory being the most commonly reported. Neurocognitive decline has been an independently associated predictor of survival in individuals with brain malignancies, and the long-term consequences of RT are usually permanent and gradual [12, 26]. Damage to white matter (WM) pathways, vascular injury, and neuroinflammation are all factors that contribute to radiation-induced brain damage. Axonal degeneration and demyelination of WM have been shown in histopathological investigations following radiation exposure, and diffusion tensor imaging (DTI) biomarkers are related to these alterations [12, 27, 28].

Based on our research, the aim of the study is to collect and classify brain diffusion MRI biomarkers after chemoradiotherapy.

Materials and methods

Search strategy

On November 12th, 2021, the search for articles was started, and on July 3rd, 2022, it was completed. Diffusion MRI, Brain, Chemoradiotherapy, Imaging Biomarker, and Neuroimaging

were among the keywords used in the search, which were entered into the following template in the PubMed electronic database and the Google Scholar search engine.

Inclusion criteria (refer to DWI biomarkers) were as follows:

- English-language original articles;
- original and review studies looked at DWI biomarkers after brain chemoradiotherapy and used MRI data;
- original research that looked at long-term cognitive and behavioral disorders.

Exclusion criteria were as follows:

- all of the articles are written in languages other than English;
- case studies and short reports;
- the studies did not employ an MRI or any other imaging modality (particularly in cases of neurological manifestations).

Literature screening

Approximately 100 publications were discovered during the first search, which comprised original studies, review articles, case reports, and short reports. As a result, case studies and short reports were excluded, but the references in the literature review were examined. After the final evaluation, 32 original papers and 6 review articles remained based on the inclusion and exclusion criteria. Biomarkers and long-term cognitive-behavioral disorders were comprehensively retrieved from all of the papers in the reference list.

The following parameters were considered throughout the search:

- first author;
- the date of publication;
- using MRI.

Finally, after doing database searches and collecting publications, they were divided into three categories: white matter changes, radiation necrosis, and neurocognitive damages.

MRI

Devices

Various investigations have employed devices of varying field strengths and commercial models to study changes in diffusion parameters in brain tissue in relation to necrotic and neurocognitive damage. The types of these devices include a 3.0T system (Philips Medical Systems, Best, the Netherlands), a 3.0T system (Achieva, Philips, Eindhoven, The Netherlands), a 3.0T 750, and 1.5 T and Signa Excite HDx scanner (General Electric Healthcare, Milwaukee, Wisconsin, United States), a Signa 1.5T and 3.0T scanner (General Electric Healthcare, Chicago, IL, United States), a Sonata 1.5T scanner (Siemens Healthcare, Erlangen, Germany), a TimeTrio 3.0T scanner (Siemens Medical Solutions, Malvern, PA, USA), and a 3.0T scanner (Trio MAGNETOM; Siemens Healthcare, Erlangen, Germany) cases. It is important to note that in some experiments, just one or even three types of a device were employed.

Diffusion-weighted techniques

DWI

DWI is a potential MRI technique for characterizing the response to RT and the damage to normal tissue. Changes in the mobility of water molecules in tissue are reflected in the MR signal in DWI. Brownian motion, as it is often referred to, is the result of heat agitation and is strongly impacted by the water's cellular structure. Neurosurgical evaluations of brain tumors may greatly benefit from DWI. One of the most commonly used parameters derived from DWI is the apparent diffusion coefficient (ADC), which quantifies the magnitude of water diffusion in tissue. ADC can provide valuable information about tumor cellularity, necrosis, edema, and perfusion, which can help in diagnosis, prognosis, treatment planning, and monitoring of brain tumors. ADC can also detect early changes in tissue microstructure after RT, which can indicate the efficacy of treatment and the risk of complications. Therefore, ADC is an important biomarker for assessing brain tumors and their response to RT [28, 29].

DTI

The advanced DTI technique is a helpful tool for measuring the damage to white matter that is caused by radiation. It is able to detect abnormalities much earlier than conventional imaging approaches. It is feasible to use the DTI's capacity to identify white matter degradation in order to determine whether or not RT has varied detrimental effects on various parts of the brain [29, 30].

We selected MD, RD, AD, and FA as biomarkers because they capture different aspects of white matter microstructure and integrity that can be altered by brain disorders. MD reflects the average diffusion of water molecules in the brain tissue, which can be affected by factors such as cell density, membrane permeability, and extracellular space. RD reflects the diffusion of water molecules orthogonal to the main fiber direction, which can be indicative of demyelination or axonal loss. AD reflects the diffusion of water molecules along the main fiber direction, which can be suggestive of axonal damage or degeneration. FA reflects the degree of anisotropy or directionality of water diffusion in the brain tissue, which can be associated with fiber coherence, organization, and alignment. These parameters have been widely used and validated in previous studies of various brain disorders, and they provide complementary information about the structural changes in white matter that may underlie the pathophysiology of these disorders. We did not use other parameters, such as mode of anisotropy or trace of the diffusion tensor, because they are less commonly used and less informative than the ones we selected [12, 27, 28].

Chemoradiation therapy techniques

Chemotherapy

Chemotherapy medications may be used after surgery, in conjunction with radiotherapy, in cases of recurrence of the disease, or even as a substitute for radiation treatment in children, depending on the patient's health. Brain tumors cannot be effectively treated with chemotherapy alone because of the blood-brain barrier (BBB) [31, 32].

External radiotherapy

Based on the type and location of the lesion, different radiotherapy techniques are used to treat brain tumors. For the most precise RT treatment, stereotactic radiosurgery (SRS) makes use of three-dimensional (3D) imaging to locate and treat brain malignancies in a single session. Some SRS techniques include the X-ray knife and the Gamma-knife [33–35].

Other methods of external radiotherapy include delivering the tumor from the outside in numerous doses. Three-dimensional conformal radiation therapy (3D-CRT) reliably identifies the planning target volume (PTV) and adjacent organs at risk (OARs) using 3D imaging [36]. In order to optimize the radiation flux profile, novel modulation systems, named intensity modulated radiation therapy (IMRT), computer-controlled multi-leaf dynamic collimators, and

methodologies such as inverse planning are required to apply this strategy [37, 38]. The most recent versions include rotating cone beams as therapy with multiple arcs at a consistent dose rate in each different sub-field of radiation or volumetric modulated arc therapies (VMAT) as treatment with rotating cone beam radiation with varying shapes and radiation intensities [39, 40].

Results and Discussion

Brain diffusion MRI biomarkers

White matter changes

Neuron myelinated fibers, also known as tracts, are found in white matter (WM), the deepest component of the brain tissue in the central nervous system. The white matter tracts of the corpus callosum and the internal capsules are crucial [41]. RT for various types of brain tumors, such as gliomas, medulloblastomas, and meningiomas, will always lead to alterations in the tumor's volume and the ratio of intracellular to extracellular volumes [42–44]. DTI and DWI, by using intrinsic tissue properties, offer a helpful quantitative evaluation of tissue structure, particularly myelinated fiber bundles in WM [45, 46].

Radiation necrosis

Focal neurological impairments are often associated with radiation necrosis, which affects mostly the white matter and is generally permanent and progressive [47]. According to the structure of the nerve fiber axons and the myelin sheath, the flow of water molecules along the length of the nerve fiber is greater than in other directions. Due to the existence of numerous membranes, restricted space, and high viscosity, the quantity of movement of water molecules in the intracellular space is smaller than that in the extracellular environment. As a result, since radiation affects the ratio of intracellular to extracellular volumes, diffusion imaging biomarkers are very useful to assess radiation damage. Utilizing these biomarkers, like other MR imaging procedures, is non-invasive and does not require any further interventions. White matter is particularly vulnerable to radiation damage because of the way water molecules move through the tissue [48]. White matter axial and radial diffusivity changes are often interpreted as

indicators of axonal injury or demyelination [49]. After beginning RT, an imaging biomarker might be used to determine the radiation sensitivity of an individual's brain normal tissue [50].

Neurocognitive damages

Neurocognitive abnormalities are clearly linked to radiation treatment and are an important adverse effect of life-saving interventions in youngsters [51]. After irradiation, cognitive loss may begin to show up months or years later and worsen with time [52]. IMRT, stereotactic radiosurgery, intracranial brachytherapy, and restricted fraction size may minimize normal tissue damage [53]. Some neuropsychological deficiencies (such as a lack of ability to recall information or spatially interpret information) still persist [54, 55].

Table 1 provides the findings that relate to alterations in diffusion biomarkers in WM changes, radiation necrosis, and neurocognitive damage. As well, Figure 1 is a representation of the common alterations that have occurred in the most significant MR diffusion biomarkers, including FA, MD, RD, AD, and ADC.

Table 1. Studies of diffusion biomarker assessment after radiation damage

Fir st Aut hor [ye ar]	Pa tie nt Nu mb ers	Ima ging Tec hniq ue(s)	Max . Dire ctio ns/b - valu es [s/m m²]	Radi othe rapy Tech niqu e(s)	Tota l dose /Fra ctio n Size [Gy]	Chemotherapy	Ima ging bio mar ker(s)	Brain tumor (s)	Chan ges in imagi ng Bioma rker(s)
White matter changes									

Chakho yan (2018) [56]	23	DWI	NA/ 0, 50, 100, 250, 500, 750, 1000, 0, 250, 0, 350 0 and 500 0	3D- CRT	60/2	Temozolomide	ADC	Glioblastoma	No difference in diffusion biomarkers change in NAWM M between pre- and post- chemo- radiation
Nagesh (2008) [6]	25	DTI	9/0 and 100 0	3D- CRT	50- 81/1. 8- 2.7	Temozolomide	FA MD AD RD	Cerebral tumors	FA decreased, and MD, RD, and AD increased in the genus

									and splenium
Hope (2015) [57]	18	DTI	15/0 and 800	3D-CRT	60/2	Temozolomide	FA MD AD RD	HGGs	In FA, no significant time evolution was observed, and there was increased MD, RD, and AD in NAWM
Haris (2008) [58]	5	DTI	10/0 and 1000	3D-CRT	54/1.8	Temozolomide	FA MD	LGGs	FA decreased and MD increased

									sed in NAW M
Tri nga le (20 19) [59]	54	DTI	15/0 , 500, 150 0, and 400 0	Prot on or phot ons RT	50.4 – 60/1. 8–2	NA	FA MD RD AD	Primar y brain tumor	where as FA decrea sed in the right caudal anterio r cingul ate, MD, RD increa sed bilater ally, where as no signifi cant chang es in AD were found during

									this time-period
Chapman (2012) [60]	10	DTI	9/0 and 1000	3D-CRT	50.4 – 59.4/1.8	NA	FA AD RD	Benign tumors	While FA was used for volume adjustment, it was not included in the analysis. Following RT, AD decreased and RD increased

Conno r (20 16) [61]	32	DTI	15/0 , 500, 150 0, and 400 0	EBR T	60/2	Chemotherapy	FA MD AD RD	HGGs	MD, AD, and RD increa sed signifi cantly with time and dose, and a corres pondin g decrea se in FA
Cha ng (20 14) [62]	15	DWI DTI	6/0 and 100 0	Parti al brain irrad iation or SRS	18– 25	NA	AD C FA	Malign ant glioma s	ADC increa sed (receiv ing more than 5 Gy) and decrea sed

									(more than 12 Gy) after 7 days and 2 months. FA decreased more after 2 months
Tibbs (2020) [63]	44	DTI	15/0, 500, 1500, and 4000	Proton therapy and IMRT or VMAT	50.4 – 70/1.8–2	NA	FA MD	Primary brain tumor	There was decreased FA in the left arcuate fasciculus, ILF, and IFOF. Increased MD in

									all of the left-sided white matter tracts, left arcuate fasciculus, ILF, IFOF
Qiu (2007) [64]	22	DTI	25/0 and 1200	3D-CRT	23.4 – 40/1.8–2	Chemotherapy	FA	Medulloblastoma	Decreased FA in the frontal lobe and parietal lobe white matter, and the frontal lobe having

									a significantly larger difference in FA compared with the parietal lobe
Connor (2017) [48]	49	DTI	15/0, 500, 1500, and 4000	3D-CRT	60/2	NA	FA, MD, AD, RD	Primary brain tumors	Decreases in FA cannot be white matter disruption. For MD, the column and body of fornix,

									cingulum bundle, tapetum, and genu and body of the corpus callosum were among the ROIs to show the most dose sensitivity
Zhu (2016) [65]	33	DTI	20/0, 800, and 1000	EBRT	50.4 – 70/2	NA	AD RD	Low-grade or benign brain tumors	There was a dose-dependent progression

									ssive decrease in AD over time after RT. RD was significantly related to maximum doses received
Ding (2017) [66]	87	DTI	NA/0 and 1000	2D-CRT or IMRT	50-76/2	Chemotherapy	FA	Nasopharyngeal carcinoma patients with normal - appearing	Within an FA mask in the putative white matter, there was a significant

								brains	cant reducti on in the FA value. Specif ically, after 12 month s of follow ups from the compl etion of RT, the FA in the bilater al spleni um of the corpus callos um was reduce d
--	--	--	--	--	--	--	--	--------	--

									compared to the pre-RT level
Human (2012) [10]	109 DTI studies (from 2020 brain tumor patients)	DTI	12/0 and 1000	3D-CRT	23.4 Gy or 36–39.6 Gy/1.8	Chemotherapy	FA	Medulloblastomas, supratentorial primitive neuroectodermal tumors, atypical teratoid rhabdoid tumors, and HGGs	Decreased FA

Raschke (2019) [67]	22	DTI	32/0 and 1000	Proton or photon therapy	13.6	Chemotherapy	MD RD AD FA	HGGs	Significant reductions in MD, RD, and AD and an increase in FA
Champan (2013) [30]	14	DTI	15/0 and 1000	3D-CRT	30 and 37.5/3 and 2.5	Chemotherapy	FA RD AD	Brain white matter structures	Significant FA decreases and RD increases. There were no significant changes in AD between

									en pre-RT and end-RT
Huynh-Le (2021) [68]	44	DTI	15/0, 500, 1500, and 4000	Proton therapy, IMRT, and VMAT	50.4 – 70/1.8–2	NA	MD FA	Primary brain tumors	Reduction in FA and an increase in MD
Sahin (2021) [69]	17	DTI	7/0 and 1000	EBRT	60/2	Chemotherapy	FA	Glioblastoma	FA decrease
Cho (2020) [70]	40	DWI	NA/0 and 1000	EBRT	NA	Chemotherapy	ADC	Glioblastoma	The ipsilesional SVZ had lower ADC values compared to

									the contral esiona l SVZ before treatm ent, as ADC values of the ipsiles ional SVZ increa sed
Kh ong (20 03) [71]	9	DTI	25/0 and 120 0	3D- CRT	30.6 –40 and 50.4 – 54/1. 8–2	NA	FA	Medul loblast oma	Signifi cant reducti on of FA was seen in all anato mic sites in the patient group compa

									red with FA in control subjects, except in the frontal periventricular WM.
Ma bbo tt (20 06) [72]	8	DWI DTI	25/0 and 100 0	3D- CRT	36- 36.6 and 23.4/ NA	Either etoposide/cisplatin/ cyclophosphamide/ vincristine or CCNU/vincristine/ cisplatin	AD C FA	Medul loblast oma	Overall, mean FA was lower and ADC was higher in the radiated group relative to

									contro ls
Rav n (20 13) [29]	19	DWI	32/0 and 130 0	3D- CRT	45– 59.4/ 1.8	NA	AD C	Astroc ytoma, pituita ry adeno ma, menin gioma, and cranio pharyn gioma	ADC increa se
Kh ong (20 06) [73]	20	DTI	25/0 and 125 0	3D- CRT	50– 55.8/ NA	Chemotherapy	FA	Childh ood MED and ALL	FA increa se
Ma kol a (20 17) [74]	22	DTI	25/0 and 100 0	EBR T	45– 59.4/ NA	With or without chemotherapy	FA RD	A pediatr ic brain tumor	The FA and RD did not chang e

									signifi cantly
Pru st (20 15) [75]	14	DWI	NA	3D- CRT	60/2	Chemotherapy	AD C	Gliobl astoma	ADC increa sed within the subve ntricul ar zone
Radiation necrosis									
Naz em- Zad eh (20 14) [76]	29	DTI	9/0 and 100 0	3D- CRT	60 and 66- 81/2 and 2.5- 2.6	Temozolomide	RD	Gliobl astoma	RD increa se
Liu (20 18) [80]	43	DWI	NA/ 0 and 100 0	EBR T	40- 50/N A	Chemotherapy	AD C	Brain metast ases from lung cancer	ADC values signifi cantly increa sed after both

									<p>one and two treatment cycles. In effective group, the ADC values were significantly increased after one and two treatment cycles. While, there are no difference in invalid</p>
--	--	--	--	--	--	--	--	--	--

									group after one treatment cycle but decreased after two treatment cycles
Feng (2022) [81]	46	DWI	20/0 and 100/0	EBR T	NA	Surgical intervention followed by chemoradiotherapy	ADC	Glioblastoma	Significant differences between the tumor recurrence from radiation necrosis groups in

									terms of ADC
Neurocognitive damages									
Tri nga le (20 19) [59]	54	DTI	15/0 , 500, 150 0, and 400 0	Prot on or phot ons RT	50.4 – 60/1. 8–2	Chemotherapy	FA MD RD AD	Gliom a and non- glioma	There were decrea ses in FA and increa ses in MD in the CAC at 3- month s post- RT. CAC chang es were charac terized by increa

									sed RD bilaterally. AD did not change significantly
Chapman (2012) [60]	10	DTI	9/0 and 1000	3D-CRT	50.4 – 59.4/ 1.8	NA	AD RD	Low-grade or benign tumors	Following RT, AD decreased and RD increased
Chapman (2016) [77]	27	DTI	20/0 and 1000	3D-CRT and IMRT	50.4 – 70/2	15% had concurrent chemotherapy with temozolomide	RD AD	Benign or low-grade tumors	Decreasing AD and increasing RD during RT

Bianchi (2018) [78]	23	DTI	32/0 and 1000	IMRT	54 and 60/1.8 and 2	Temozolomid	FA	HGGs	FA in the contralateral hippocampus decreased at 6 and 9 months after radiotherapy. FA in the ipsilateral hippocampus before radiotherapy decreased compared with 6 months after
---------------------	----	-----	---------------	------	---------------------	-------------	----	------	--

									radiot herapy
Tri nga le (20 19) [12]	27	DTI	15/0 , 500, 150 0, and 400 0	IMR T and proto n thera py	50.4 – 60/1. 8-2	Chemotherapy	FA MD	Primar y brain tumor	Decre asing FA and increa sing MD
La w (20 11) [79]	67	DTI	31/0 and 100 0	3D- CRT	23.4 – 36/N A	Chemotherapy	FA RD MD	Posteri or fossa tumor	All imagin g bioma rkers have not chang ed signifi cantly

DWI — diffusion-weighted imaging; NA — non available; 3D-CRT — three-dimensional conformal radiation therapy; ADC — apparent diffusion coefficient; NAWM — normal-appearing white matter; DTI — diffusion tensor imagin; FA — fractional anisotropy; MD — mean diffusivity; AD — axial diffusivity; RD — radial diffusivity; HGGs — high-grade gliomas; LGGs — low-grade gliomas; RT — radiation therapy; EBRT — external beam radiation radiation therapy; SRS — stereotactic radiosurger; IMRT — intensity modulated radiation therapy; VMAT — volumetric modulated arc therapy; ILF — inferior longitudinal

fasciculus; IFOF — inferior fronto-occipital fasciculus; ROIs — regions of interest; 2D-CRT — 2-dimensional conformal radiation therapy; SVZ — subventricular zone; CCNU — lomustine; MED — medulloblastoma; ALL — acute lymphoblastic leukemia; CAC — caudal anterior cingulate

Radiation Damages	MR Diffusion Biomarker Changes				
	FA	MD	RD	AD	ADC
White Matter Changes	↓	↑	↑	↕	Dependent on Radiation Dose
Radiation Necrosis	N/A	N/A	↑	N/A	N/A
Neurocognitive Damages	↓	↑	↑	N/A	N/A

Figure 1. Magnetic resonance (MR) diffusion biomarkers changes. N/A — non available

FA — fractional anisotropy; MD — mean diffusivity; RD — radial diffusivity; AD — axial diffusivity; ADC — apparent diffusion coefficient

Conclusion

Neuroimaging biomarkers after chemoradiotherapy were evaluated using diffusion imaging methods (DWI and DTI). We found that biomarkers change depending on the degree of tissue damage. Some studies demonstrate that biomarker alterations are increasing, while others show that they are decreasing. As a consequence, there is disagreement over the general pattern of change. Even so, FA changes are predicted to decrease, whereas MD and RD changes are

expected to increase. It is proposed that further longitudinal studies be conducted to determine the effectiveness of diffusion imaging biomarkers.

Conflict of interest

The authors declare no financial or other conflicts of interest.

Funding

No funding.

Author's Contributions

S.G. and M.M. contributed to the conception and design of the study; Sh.B., F.M., M.Z., and Gh.T. contributed to the data collection. S.G. and M.M. contributed to drafting the text and preparing the Figure 1.

Ethical statement

No human or animal subjects were used in the research.

References

1. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. *J Magn Reson Imaging*. 1999; 9(1): 53-60, doi: [10.1002/\(sici\)1522-2586\(199901\)9:1<53::aid-jmri7>3.0.co;2-2](https://doi.org/10.1002/(sici)1522-2586(199901)9:1<53::aid-jmri7>3.0.co;2-2), indexed in Pubmed: [10030650](https://pubmed.ncbi.nlm.nih.gov/10030650/).
2. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. *Radiology*. 2006; 239(3): 632-649, doi: [10.1148/radiol.2393042031](https://doi.org/10.1148/radiol.2393042031), indexed in Pubmed: [16714455](https://pubmed.ncbi.nlm.nih.gov/16714455/).
3. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. *Magn Reson Med*. 2000; 43(6): 828-836, doi: [10.1002/1522-2594\(200006\)43:6<828::aid-mrm8>3.0.co;2-p](https://doi.org/10.1002/1522-2594(200006)43:6<828::aid-mrm8>3.0.co;2-p), indexed in Pubmed: [10861877](https://pubmed.ncbi.nlm.nih.gov/10861877/).
4. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. *J Magn Reson Imaging*. 2010; 31(3): 538-548, doi: [10.1002/jmri.22068](https://doi.org/10.1002/jmri.22068), indexed in Pubmed: [20187195](https://pubmed.ncbi.nlm.nih.gov/20187195/).

5. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. *J Natl Cancer Inst.* 2000; 92(24): 2029-2036, doi: [10.1093/jnci/92.24.2029](https://doi.org/10.1093/jnci/92.24.2029), indexed in Pubmed: [11121466](https://pubmed.ncbi.nlm.nih.gov/11121466/).
6. Nagesh V, Tsien CI, Chenevert TL, et al. Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. *Int J Radiat Oncol Biol Phys.* 2008; 70(4): 1002-1010, doi: [10.1016/j.ijrobp.2007.08.020](https://doi.org/10.1016/j.ijrobp.2007.08.020), indexed in Pubmed: [18313524](https://pubmed.ncbi.nlm.nih.gov/18313524/).
7. Ye-Ting Z, Wang GS, Chen XD, et al. MRI Finding in Delayed Extensive Brain Lesions after Radiation Therapy :Cortical Laminar Necrosis and White Matter Myelinolysis. *Adv Mol Imag.* 2012; 02(01): 1-3, doi: [10.4236/ami.2012.21001](https://doi.org/10.4236/ami.2012.21001).
8. Chan KC, Khong PL, Cheung MM, et al. MRI of late microstructural and metabolic alterations in radiation-induced brain injuries. *J Magn Reson Imaging.* 2009; 29(5): 1013-1020, doi: [10.1002/jmri.21736](https://doi.org/10.1002/jmri.21736), indexed in Pubmed: [19388094](https://pubmed.ncbi.nlm.nih.gov/19388094/).
9. Sundgren PC, Cao Y, Sundgren PC, et al. Metabolic alterations: a biomarker for radiation-induced normal brain injury-an MR spectroscopy study. *J Magn Reson Imaging.* 2009; 29(2): 291-297, doi: [10.1002/jmri.21657](https://doi.org/10.1002/jmri.21657), indexed in Pubmed: [19161192](https://pubmed.ncbi.nlm.nih.gov/19161192/).
10. Hua C, Merchant TE, Gajjar A, et al. Brain tumor therapy-induced changes in normal-appearing brainstem measured with longitudinal diffusion tensor imaging. *Int J Radiat Oncol Biol Phys.* 2012; 82(5): 2047-2054, doi: [10.1016/j.ijrobp.2011.03.057](https://doi.org/10.1016/j.ijrobp.2011.03.057), indexed in Pubmed: [21664060](https://pubmed.ncbi.nlm.nih.gov/21664060/).
11. Li Z, Peck KK, Brennan NP, et al. Diffusion tensor tractography of the arcuate fasciculus in patients with brain tumors: Comparison between deterministic and probabilistic models. *J Biomed Sci Eng.* 2013; 6(2): 192-200, doi: [10.4236/jbise.2013.62023](https://doi.org/10.4236/jbise.2013.62023), indexed in Pubmed: [25328583](https://pubmed.ncbi.nlm.nih.gov/25328583/).
12. Tringale KR, Nguyen TT, Karunamuni R, et al. Quantitative Imaging Biomarkers of Damage to Critical Memory Regions Are Associated With Post-Radiation Therapy Memory Performance in Brain Tumor Patients. *Int J Radiat Oncol Biol Phys.* 2019; 105(4): 773-783, doi: [10.1016/j.ijrobp.2019.08.003](https://doi.org/10.1016/j.ijrobp.2019.08.003), indexed in Pubmed: [31408667](https://pubmed.ncbi.nlm.nih.gov/31408667/).
13. Hancock C, Bernal B, Medina C, et al. Cost Analysis of Diffusion Tensor Imaging and MR Tractography of the Brain. *Open J Radiol.* 2014; 04(03): 260-269, doi: [10.4236/ojrad.2014.43034](https://doi.org/10.4236/ojrad.2014.43034).
14. Mac Donald CL, Dikranian K, Bayly P, et al. Diffusion tensor imaging reliably detects experimental traumatic axonal injury and indicates approximate time of injury. *J Neurosci.* 2007; 27(44): 11869-11876, doi: [10.1523/JNEUROSCI.3647-07.2007](https://doi.org/10.1523/JNEUROSCI.3647-07.2007), indexed in Pubmed: [17978027](https://pubmed.ncbi.nlm.nih.gov/17978027/).
15. Song SK, Sun SW, Ramsbottom MJ, et al. Dysmyelination revealed through MRI as increased radial (but unchanged axial) diffusion of water. *Neuroimage.* 2002; 17(3): 1429-1436, doi: [10.1006/nimg.2002.1267](https://doi.org/10.1006/nimg.2002.1267), indexed in Pubmed: [12414282](https://pubmed.ncbi.nlm.nih.gov/12414282/).
16. Grigoriadis N, Ben-Hur T, Karussis D, et al. Axonal damage in multiple sclerosis: a complex issue in a complex disease. *Clin Neurol Neurosurg.* 2004; 106(3): 211-217, doi: [10.1016/j.clineuro.2004.02.017](https://doi.org/10.1016/j.clineuro.2004.02.017), indexed in Pubmed: [15177770](https://pubmed.ncbi.nlm.nih.gov/15177770/).

17. Sun SW, Liang HF, Cross AH, et al. Evolving Wallerian degeneration after transient retinal ischemia in mice characterized by diffusion tensor imaging. *Neuroimage*. 2008; 40(1): 1-10, doi: [10.1016/j.neuroimage.2007.11.049](https://doi.org/10.1016/j.neuroimage.2007.11.049), indexed in Pubmed: [18187343](https://pubmed.ncbi.nlm.nih.gov/18187343/).
18. Chi A, Komaki R. Treatment of brain metastasis from lung cancer. *Cancers (Basel)*. 2010; 2(4): 2100-2137, doi: [10.3390/cancers2042100](https://doi.org/10.3390/cancers2042100), indexed in Pubmed: [24281220](https://pubmed.ncbi.nlm.nih.gov/24281220/).
19. Shi L, Olson J, D'Agostino R, et al. Aging masks detection of radiation-induced brain injury. *Brain Res*. 2011; 1385: 307-316, doi: [10.1016/j.brainres.2011.02.034](https://doi.org/10.1016/j.brainres.2011.02.034), indexed in Pubmed: [21338580](https://pubmed.ncbi.nlm.nih.gov/21338580/).
20. Greene-Schloesser D, Moore E, Robbins ME. Molecular pathways: radiation-induced cognitive impairment. *Clin Cancer Res*. 2013; 19(9): 2294-2300, doi: [10.1158/1078-0432.CCR-11-2903](https://doi.org/10.1158/1078-0432.CCR-11-2903), indexed in Pubmed: [23388505](https://pubmed.ncbi.nlm.nih.gov/23388505/).
21. Moore ED, Kooshki M, Wheeler KT, et al. Differential expression of Homer1a in the hippocampus and cortex likely plays a role in radiation-induced brain injury. *Radiat Res*. 2014; 181(1): 21-32, doi: [10.1667/RR13475.1](https://doi.org/10.1667/RR13475.1), indexed in Pubmed: [24377717](https://pubmed.ncbi.nlm.nih.gov/24377717/).
22. Wu PH, Coultrap S, Pinnix C, et al. Radiation induces acute alterations in neuronal function. *PLoS One*. 2012; 7(5): e37677, doi: [10.1371/journal.pone.0037677](https://doi.org/10.1371/journal.pone.0037677), indexed in Pubmed: [22662188](https://pubmed.ncbi.nlm.nih.gov/22662188/).
23. Makale MT, McDonald CR, Hattangadi-Gluth J, et al. Brain irradiation and long-term cognitive disability: Current concepts. *Nature Rev Neurol*. 2017; 13(1): 52.
24. Jenrow KA, Brown SL, Lapanowski K, et al. Selective inhibition of microglia-mediated neuroinflammation mitigates radiation-induced cognitive impairment. *Radiat Res*. 2013; 179(5): 549-556, doi: [10.1667/RR3026.1](https://doi.org/10.1667/RR3026.1), indexed in Pubmed: [23560629](https://pubmed.ncbi.nlm.nih.gov/23560629/).
25. Lippitz B, Lindquist C, Paddick I, et al. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. *Cancer Treat Rev*. 2014; 40(1): 48-59, doi: [10.1016/j.ctrv.2013.05.002](https://doi.org/10.1016/j.ctrv.2013.05.002), indexed in Pubmed: [23810288](https://pubmed.ncbi.nlm.nih.gov/23810288/).
26. Greene-Schloesser D, Robbins ME. Radiation-induced cognitive impairment--from bench to bedside. *Neuro Oncol*. 2012; 14 Suppl 4(Suppl 4): iv37-iv44, doi: [10.1093/neuonc/nos196](https://doi.org/10.1093/neuonc/nos196), indexed in Pubmed: [23095829](https://pubmed.ncbi.nlm.nih.gov/23095829/).
27. Panagiotakos G, Alshamy G, Chan B, et al. Long-term impact of radiation on the stem cell and oligodendrocyte precursors in the brain. *PLoS One*. 2007; 2(7): e588, doi: [10.1371/journal.pone.0000588](https://doi.org/10.1371/journal.pone.0000588), indexed in Pubmed: [17622341](https://pubmed.ncbi.nlm.nih.gov/17622341/).
28. Hung P, Tohyama S, Zhang JY, et al. Temporal disconnection between pain relief and trigeminal nerve microstructural changes after Gamma Knife radiosurgery for trigeminal neuralgia. *J Neurosurg*. 2019 [Epub ahead of print]: 1-9, doi: [10.3171/2019.4.JNS19380](https://doi.org/10.3171/2019.4.JNS19380), indexed in Pubmed: [31299654](https://pubmed.ncbi.nlm.nih.gov/31299654/).
29. Ravn S, Holmberg M, Sørensen P, et al. Differences in supratentorial white matter diffusion after radiotherapy--new biomarker of normal brain tissue damage? *Acta Oncol*. 2013; 52(7): 1314-1319, doi: [10.3109/0284186X.2013.812797](https://doi.org/10.3109/0284186X.2013.812797), indexed in Pubmed: [23981047](https://pubmed.ncbi.nlm.nih.gov/23981047/).
30. Chapman CH, Nazem-Zadeh M, Lee OE, et al. Regional variation in brain white matter diffusion index changes following chemoradiotherapy: a prospective study using tract-based spatial

statistics. PLoS One. 2013; 8(3): e57768, doi: [10.1371/journal.pone.0057768](https://doi.org/10.1371/journal.pone.0057768), indexed in Pubmed: [23469234](https://pubmed.ncbi.nlm.nih.gov/23469234/).

31. Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. *Nat Rev Cancer*. 2020; 20(1): 26–41, doi: [10.1038/s41568-019-0205-x](https://doi.org/10.1038/s41568-019-0205-x), indexed in Pubmed: [31601988](https://pubmed.ncbi.nlm.nih.gov/31601988/).
32. Patel JP, Spiller SE, Barker ED. Drug penetration in pediatric brain tumors: Challenges and opportunities. *Pediatr Blood Cancer*. 2021; 68(6): e28983, doi: [10.1002/psc.28983](https://doi.org/10.1002/psc.28983), indexed in Pubmed: [33719183](https://pubmed.ncbi.nlm.nih.gov/33719183/).
33. Redmond KJ, Gui C, Benedict S, et al. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases. *Int J Radiat Oncol Biol Phys*. 2021; 110(1): 53–67, doi: [10.1016/j.ijrobp.2020.10.034](https://doi.org/10.1016/j.ijrobp.2020.10.034), indexed in Pubmed: [33390244](https://pubmed.ncbi.nlm.nih.gov/33390244/).
34. Shah JL, Li G, Shaffer JL, et al. Stereotactic Radiosurgery and Hypofractionated Radiotherapy for Glioblastoma. *Neurosurgery*. 2018; 82(1): 24–34, doi: [10.1093/neuros/nyx115](https://doi.org/10.1093/neuros/nyx115), indexed in Pubmed: [28605463](https://pubmed.ncbi.nlm.nih.gov/28605463/).
35. Leksell L. The stereotactic method and radiosurgery of the brain. *Acta Chir Scand*. 1951; 102: 316–9.
36. Pelizzari CA, Chen GT, Spelbring DR, et al. Accurate three-dimensional registration of CT, PET, and/or MR images of the brain. *J Comput Assist Tomogr*. 1989; 13(1): 20–26, doi: [10.1097/00004728-198901000-00004](https://doi.org/10.1097/00004728-198901000-00004), indexed in Pubmed: [2492038](https://pubmed.ncbi.nlm.nih.gov/2492038/).
37. Bortfeld T. IMRT: a review and preview. *Phys Med Biol*. 2006; 51(13): R363–R379, doi: [10.1088/0031-9155/51/13/r21](https://doi.org/10.1088/0031-9155/51/13/r21).
38. Cho B, Cho B. Intensity-modulated radiation therapy: a review with a physics perspective. *Radiat Oncol J*. 2018; 36(1): 1–10, doi: [10.3857/roj.2018.00122](https://doi.org/10.3857/roj.2018.00122), indexed in Pubmed: [29621869](https://pubmed.ncbi.nlm.nih.gov/29621869/).
39. Lafond C, Jouyaux F, Bellec J, et al. [Which IMRT? From "step and shoot" to VMAT: physicist point of view]. *Cancer Radiother*. 2010; 14(6-7): 539–549, doi: [10.1016/j.canrad.2010.06.012](https://doi.org/10.1016/j.canrad.2010.06.012), indexed in Pubmed: [20728394](https://pubmed.ncbi.nlm.nih.gov/20728394/).
40. Muzumder S, John Sebastian MG. Plan Evaluation in IMRT and VMAT. In: Mallick S, Rath GK, Benson R. ed. *Practical Radiation Oncology*. Springer, Singapore 2020: 151–156.
41. Buyanova IS, Arsalidou M. Cerebral White Matter Myelination and Relations to Age, Gender, and Cognition: A Selective Review. *Front Hum Neurosci*. 2021; 15: 662031, doi: [10.3389/fnhum.2021.662031](https://doi.org/10.3389/fnhum.2021.662031), indexed in Pubmed: [34295229](https://pubmed.ncbi.nlm.nih.gov/34295229/).
42. Barani IJ, Larson DA. Radiation therapy of glioblastoma. *Cancer Treat Res*. 2015; 163: 49–73, doi: [10.1007/978-3-319-12048-5_4](https://doi.org/10.1007/978-3-319-12048-5_4), indexed in Pubmed: [25468225](https://pubmed.ncbi.nlm.nih.gov/25468225/).
43. Balducci M, Chiesa S, Chieffo D, et al. The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature. *J Neurooncol*. 2012; 106(2): 315–323, doi: [10.1007/s11060-011-0665-7](https://doi.org/10.1007/s11060-011-0665-7), indexed in Pubmed: [21805324](https://pubmed.ncbi.nlm.nih.gov/21805324/).
44. Pinzi V, Bisogno I, Prada F, et al. Radiotherapy of meningioma: a treatment in need of radiobiological research. *Int J Radiat Biol*. 2018; 94(7): 621–627, doi: [10.1080/09553002.2018.1478157](https://doi.org/10.1080/09553002.2018.1478157), indexed in Pubmed: [29775403](https://pubmed.ncbi.nlm.nih.gov/29775403/).

45. Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging: concepts and applications. *J Magn Reson Imaging*. 2001; 13(4): 534–546, doi: [10.1002/jmri.1076](https://doi.org/10.1002/jmri.1076), indexed in Pubmed: [11276097](https://pubmed.ncbi.nlm.nih.gov/11276097/).
46. Johansen-Berg H. Behavioural relevance of variation in white matter microstructure. *Curr Opin Neurol*. 2010; 23(4): 351–358, doi: [10.1097/WCO.0b013e32833b7631](https://doi.org/10.1097/WCO.0b013e32833b7631), indexed in Pubmed: [20581685](https://pubmed.ncbi.nlm.nih.gov/20581685/).
47. Fink J, Born D, Chamberlain MC. Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors. *Curr Neurol Neurosci Rep*. 2012; 12(3): 276–285, doi: [10.1007/s11910-012-0258-7](https://doi.org/10.1007/s11910-012-0258-7), indexed in Pubmed: [22350279](https://pubmed.ncbi.nlm.nih.gov/22350279/).
48. Connor M, Karunamuni R, McDonald C, et al. Regional susceptibility to dose-dependent white matter damage after brain radiotherapy. *Radiother Oncol*. 2017; 123(2): 209–217, doi: [10.1016/j.radonc.2017.04.006](https://doi.org/10.1016/j.radonc.2017.04.006), indexed in Pubmed: [28460824](https://pubmed.ncbi.nlm.nih.gov/28460824/).
49. Song SK, Sun SW, Ju WK, et al. Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. *Neuroimage*. 2003; 20(3): 1714–1722, doi: [10.1016/j.neuroimage.2003.07.005](https://doi.org/10.1016/j.neuroimage.2003.07.005), indexed in Pubmed: [14642481](https://pubmed.ncbi.nlm.nih.gov/14642481/).
50. Jeraj R, Cao Y, Ten Haken RK, et al. Imaging for assessment of radiation-induced normal tissue effects. *Int J Radiat Oncol Biol Phys*. 2010; 76(3 Suppl): S140–S144, doi: [10.1016/j.ijrobp.2009.08.077](https://doi.org/10.1016/j.ijrobp.2009.08.077), indexed in Pubmed: [20171509](https://pubmed.ncbi.nlm.nih.gov/20171509/).
51. Askins MA, Moore BD. Preventing neurocognitive late effects in childhood cancer survivors. *J Child Neurol*. 2008; 23(10): 1160–1171, doi: [10.1177/0883073808321065](https://doi.org/10.1177/0883073808321065), indexed in Pubmed: [18952582](https://pubmed.ncbi.nlm.nih.gov/18952582/).
52. Monje M, Dietrich J. Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. *Behav Brain Res*. 2012; 227(2): 376–379, doi: [10.1016/j.bbr.2011.05.012](https://doi.org/10.1016/j.bbr.2011.05.012), indexed in Pubmed: [21621557](https://pubmed.ncbi.nlm.nih.gov/21621557/).
53. Baskar R, Lee KA, Yeo R, et al. Cancer and radiation therapy: current advances and future directions. *Int J Med Sci*. 2012; 9(3): 193–199, doi: [10.7150/ijms.3635](https://doi.org/10.7150/ijms.3635), indexed in Pubmed: [22408567](https://pubmed.ncbi.nlm.nih.gov/22408567/).
54. Pazzaglia S, Briganti G, Mancuso M, et al. Neurocognitive Decline Following Radiotherapy: Mechanisms and Therapeutic Implications. *Cancers (Basel)*. 2020; 12(1), doi: [10.3390/cancers12010146](https://doi.org/10.3390/cancers12010146), indexed in Pubmed: [31936195](https://pubmed.ncbi.nlm.nih.gov/31936195/).
55. Michaelidesová A, Konířová J, Bartůněk P, et al. Differentiation Induction as a Response to Irradiation in Neural Stem Cells In Vitro. *Cancers (Basel)*. 2019; 11(7), doi: [10.3390/cancers11070913](https://doi.org/10.3390/cancers11070913), indexed in Pubmed: [31261863](https://pubmed.ncbi.nlm.nih.gov/31261863/).
56. Chakhoyan A, Woodworth DC, Harris RJ, et al. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. *J Neurooncol*. 2018; 139(3): 651–659, doi: [10.1007/s11060-018-2910-9](https://doi.org/10.1007/s11060-018-2910-9), indexed in Pubmed: [29855771](https://pubmed.ncbi.nlm.nih.gov/29855771/).
57. Hope TR, Vardal J, Bjørnerud A, et al. Serial diffusion tensor imaging for early detection of radiation-induced injuries to normal-appearing white matter in high-grade glioma patients. *J Magn Reson Imaging*. 2015; 41(2): 414–423, doi: [10.1002/jmri.24533](https://doi.org/10.1002/jmri.24533), indexed in Pubmed: [24399480](https://pubmed.ncbi.nlm.nih.gov/24399480/).

58. Haris M, Kumar S, Raj MK, et al. Serial diffusion tensor imaging to characterize radiation-induced changes in normal-appearing white matter following radiotherapy in patients with adult low-grade gliomas. *Radiat Med.* 2008; 26(3): 140-150, doi: [10.1007/s11604-007-0209-4](https://doi.org/10.1007/s11604-007-0209-4), indexed in Pubmed: [18683569](https://pubmed.ncbi.nlm.nih.gov/18683569/).
59. Tringale KR, Nguyen T, Bahrami N, et al. Identifying early diffusion imaging biomarkers of regional white matter injury as indicators of executive function decline following brain radiotherapy: A prospective clinical trial in primary brain tumor patients. *Radiother Oncol.* 2019; 132: 27-33, doi: [10.1016/j.radonc.2018.11.018](https://doi.org/10.1016/j.radonc.2018.11.018), indexed in Pubmed: [30825966](https://pubmed.ncbi.nlm.nih.gov/30825966/).
60. Chapman CH, Nagesh V, Sundgren PC, et al. Diffusion tensor imaging of normal-appearing white matter as biomarker for radiation-induced late delayed cognitive decline. *Int J Radiat Oncol Biol Phys.* 2012; 82(5): 2033-2040, doi: [10.1016/j.ijrobp.2011.01.068](https://doi.org/10.1016/j.ijrobp.2011.01.068), indexed in Pubmed: [21570218](https://pubmed.ncbi.nlm.nih.gov/21570218/).
61. Connor M, Karunamuni R, McDonald C, et al. Dose-dependent white matter damage after brain radiotherapy. *Radiother Oncol.* 2016; 121(2): 209-216, doi: [10.1016/j.radonc.2016.10.003](https://doi.org/10.1016/j.radonc.2016.10.003), indexed in Pubmed: [27776747](https://pubmed.ncbi.nlm.nih.gov/27776747/).
62. Chang Z, Kirkpatrick JP, Wang Z, et al. Evaluating radiation-induced white matter changes in patients treated with stereotactic radiosurgery using diffusion tensor imaging: a pilot study. *Technol Cancer Res Treat.* 2014; 13(1): 21-28, doi: [10.7785/tcrt.2012.500358](https://doi.org/10.7785/tcrt.2012.500358), indexed in Pubmed: [23862743](https://pubmed.ncbi.nlm.nih.gov/23862743/).
63. Tibbs MD, Huynh-Le MP, Karunamuni R, et al. Microstructural Injury to Left-Sided Perisylvian White Matter Predicts Language Decline After Brain Radiation Therapy. *Int J Radiat Oncol Biol Phys.* 2020; 108(5): 1218-1228, doi: [10.1016/j.ijrobp.2020.07.032](https://doi.org/10.1016/j.ijrobp.2020.07.032), indexed in Pubmed: [32712255](https://pubmed.ncbi.nlm.nih.gov/32712255/).
64. Qiu D, Kwong DLW, Chan GCF, et al. Diffusion tensor magnetic resonance imaging finding of discrepant fractional anisotropy between the frontal and parietal lobes after whole-brain irradiation in childhood medulloblastoma survivors: reflection of regional white matter radiosensitivity? *Int J Radiat Oncol Biol Phys.* 2007; 69(3): 846-851, doi: [10.1016/j.ijrobp.2007.04.041](https://doi.org/10.1016/j.ijrobp.2007.04.041), indexed in Pubmed: [17544593](https://pubmed.ncbi.nlm.nih.gov/17544593/).
65. Zhu T, Chapman CH, Tsien C, et al. Effect of the Maximum Dose on White Matter Fiber Bundles Using Longitudinal Diffusion Tensor Imaging. *Int J Radiat Oncol Biol Phys.* 2016; 96(3): 696-705, doi: [10.1016/j.ijrobp.2016.07.010](https://doi.org/10.1016/j.ijrobp.2016.07.010), indexed in Pubmed: [27681767](https://pubmed.ncbi.nlm.nih.gov/27681767/).
66. Ding Z, Zhang H, Lv XF, et al. Radiation-induced brain structural and functional abnormalities in presymptomatic phase and outcome prediction. *Hum Brain Mapp.* 2018; 39(1): 407-427, doi: [10.1002/hbm.23852](https://doi.org/10.1002/hbm.23852), indexed in Pubmed: [29058342](https://pubmed.ncbi.nlm.nih.gov/29058342/).
67. Raschke F, Wesemann T, Wahl H, et al. Reduced diffusion in normal appearing white matter of glioma patients following radio(chemo)therapy. *Radiother Oncol.* 2019; 140: 110-115, doi: [10.1016/j.radonc.2019.06.022](https://doi.org/10.1016/j.radonc.2019.06.022), indexed in Pubmed: [31265941](https://pubmed.ncbi.nlm.nih.gov/31265941/).
68. Huynh-Le MP, Tibbs MD, Karunamuni R, et al. Microstructural Injury to Corpus Callosum and Intrahemispheric White Matter Tracts Correlate With Attention and Processing Speed Decline After Brain Radiation. *Int J Radiat Oncol Biol Phys.* 2021; 110(2): 337-347, doi: [10.1016/j.ijrobp.2020.12.046](https://doi.org/10.1016/j.ijrobp.2020.12.046), indexed in Pubmed: [33412257](https://pubmed.ncbi.nlm.nih.gov/33412257/).

69. Şahin S, Ertekin E, Şahin T, et al. Evaluation of normal-appearing white matter with perfusion and diffusion MRI in patients with treated glioblastoma. *MAGMA*. 2022; 35(1): 153-162, doi: [10.1007/s10334-021-00990-5](https://doi.org/10.1007/s10334-021-00990-5), indexed in Pubmed: [34951690](https://pubmed.ncbi.nlm.nih.gov/34951690/).
70. Cho N, Wang C, Raymond C, et al. Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. *J Neurooncol*. 2020; 147(3): 643-652, doi: [10.1007/s11060-020-03460-5](https://doi.org/10.1007/s11060-020-03460-5), indexed in Pubmed: [32239430](https://pubmed.ncbi.nlm.nih.gov/32239430/).
71. Khong PL, Kwong DLW, Chan GCF, et al. Diffusion-tensor imaging for the detection and quantification of treatment-induced white matter injury in children with medulloblastoma: a pilot study. *AJNR Am J Neuroradiol*. 2003; 24(4): 734-740, indexed in Pubmed: [12695214](https://pubmed.ncbi.nlm.nih.gov/12695214/).
72. Mabbott DJ, Noseworthy MD, Bouffet E, et al. Diffusion tensor imaging of white matter after cranial radiation in children for medulloblastoma: correlation with IQ. *Neuro Oncol*. 2006; 8(3): 244-252, doi: [10.1215/15228517-2006-002](https://doi.org/10.1215/15228517-2006-002), indexed in Pubmed: [16723629](https://pubmed.ncbi.nlm.nih.gov/16723629/).
73. Khong PL, Leung LHT, Fung ASM, et al. White matter anisotropy in post-treatment childhood cancer survivors: preliminary evidence of association with neurocognitive function. *J Clin Oncol*. 2006; 24(6): 884-890, doi: [10.1200/JCO.2005.02.4505](https://doi.org/10.1200/JCO.2005.02.4505), indexed in Pubmed: [16484697](https://pubmed.ncbi.nlm.nih.gov/16484697/).
74. Makola M, Douglas Ris M, Mahone EM, et al. Long-term effects of radiation therapy on white matter of the corpus callosum: a diffusion tensor imaging study in children. *Pediatr Radiol*. 2017; 47(13): 1809-1816, doi: [10.1007/s00247-017-3955-1](https://doi.org/10.1007/s00247-017-3955-1), indexed in Pubmed: [28844078](https://pubmed.ncbi.nlm.nih.gov/28844078/).
75. Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, et al. Standard chemoradiation for glioblastoma results in progressive brain volume loss. *Neurology*. 2015; 85(8): 683-691, doi: [10.1212/WNL.0000000000001861](https://doi.org/10.1212/WNL.0000000000001861), indexed in Pubmed: [26208964](https://pubmed.ncbi.nlm.nih.gov/26208964/).
76. Nazem-Zadeh MR, Chapman CH, Chenevert T, et al. Response-driven imaging biomarkers for predicting radiation necrosis of the brain. *Phys Med Biol*. 2014; 59(10): 2535-2547, doi: [10.1088/0031-9155/59/10/2535](https://doi.org/10.1088/0031-9155/59/10/2535), indexed in Pubmed: [24778364](https://pubmed.ncbi.nlm.nih.gov/24778364/).
77. Chapman CH, Zhu T, Nazem-Zadeh M, et al. Diffusion tensor imaging predicts cognitive function change following partial brain radiotherapy for low-grade and benign tumors. *Radiother Oncol*. 2016; 120(2): 234-240, doi: [10.1016/j.radonc.2016.06.021](https://doi.org/10.1016/j.radonc.2016.06.021), indexed in Pubmed: [27418525](https://pubmed.ncbi.nlm.nih.gov/27418525/).
78. Bian Y, Meng Li, Peng J, et al. Effect of radiochemotherapy on the cognitive function and diffusion tensor and perfusion weighted imaging for high-grade gliomas: A prospective study. *Sci Rep*. 2019; 9(1): 5967, doi: [10.1038/s41598-019-42321-8](https://doi.org/10.1038/s41598-019-42321-8), indexed in Pubmed: [30979930](https://pubmed.ncbi.nlm.nih.gov/30979930/).
79. Law N, Bouffet E, Laughlin S, et al. Cerebello-thalamo-cerebral connections in pediatric brain tumor patients: impact on working memory. *Neuroimage*. 2011; 56(4): 2238-2248, doi: [10.1016/j.neuroimage.2011.03.065](https://doi.org/10.1016/j.neuroimage.2011.03.065), indexed in Pubmed: [21473922](https://pubmed.ncbi.nlm.nih.gov/21473922/).
80. Liu K, Ma Z, Feng L. Apparent diffusion coefficient as an effective index for the therapeutic efficiency of brain chemoradiotherapy for brain metastases from lung cancer. *BMC Med Imaging*. 2018; 18(1): 30, doi: [10.1186/s12880-018-0275-3](https://doi.org/10.1186/s12880-018-0275-3), indexed in Pubmed: [30223786](https://pubmed.ncbi.nlm.nih.gov/30223786/).
81. Feng A, Yuan P, Huang T, et al. Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI. *Acad Radiol*. 2022; 29(9): 1320-1331, doi: [10.1016/j.acra.2021.11.008](https://doi.org/10.1016/j.acra.2021.11.008), indexed in Pubmed: [34896001](https://pubmed.ncbi.nlm.nih.gov/34896001/).